cs.AIMar 30, 2026

What an Autonomous Agent Discovers About Molecular Transformer Design: Does It Transfer?

Authors: Edward Wijaya

Organizations: StemRIM, Inc.

Abstract

Deep learning models for drug-like molecules and proteins overwhelmingly reuse transformer architectures designed for natural language, yet whether molecular sequences benefit from different designs has not been systematically tested. We deploy autonomous architecture search via an agent across three sequence types (SMILES, protein, and English text as control), running 3,106 experiments on a single GPU. For SMILES, architecture search is counterproductive: tuning learning rates and schedules alone outperforms the full search (p = 0.001). For natural language, architecture changes drive 81% of improvement (p = 0.009). Proteins fall between the two. Surprisingly, although the agent discovers distinct architectures per domain (p = 0.004), every innovation transfers across all three domains with <1% degradation, indicating that the differences reflect search-path dependence rather than fundamental biological requirements. We release a decision framework and open-source toolkit for molecular modeling teams to choose between autonomous architecture search and simple hyperparameter tuning.

Explore similar work

Oct 13, 2026

PairIT: Autoregressive Transformers for Low-Data Molecule Optimization

Generating novel molecules with desired properties is a central challenge in drug discovery. Although foundational work focused on de novo generation, practical use cases require a more complex setting: conditioning on an initial seed molecule, optimizing multiple properties, and operating in data-sparse regimes. We introduce PairIT, a flexible training framework for autoregressive transformers over SMILES sequences that enables seeded generation by learning from pairs of structurally similar molecules. By leveraging matched pairs, the model learns to generate local, chemically meaningful edits that improve a property of the seed molecule. Prompt tokens extend this framework by specifying the target property, desired direction, and approximate magnitude of change. Multiple prompt tokens can be concatenated to enable multi-property optimization at inference time. For properties where pair supervision alone is insufficient, reinforcement learning post-training can further improve optimization, providing a tunable trade-off between proximity to the seed and the optimization objective. PairIT naturally supports pretraining on a large dataset and fine-tuning on a smaller dataset, which is critical for performance in data-sparse regimes. Surprisingly, we observe diminishing returns to the scale of the pretraining dataset. We demonstrate empirically on MoleculeNet and Therapeutics Data Commons datasets that, with appropriate paired-data curation, a standard transformer model of modest size (68M parameters) can achieve robust seeded molecular optimization in low-data regimes.
May 7, 2026

SMolLM: Small Language Models Learn Small Molecular Grammar

Language models for molecular design have scaled to hundreds of millions of parameters, yet how they learn chemical grammar is poorly understood. We train SMolLM, a 53K-parameter weight-shared transformer, to generate novel SMILES with 95% validity on the ZINC-250K drug-like-molecule benchmark, outperforming a standard GPT with 10 times more parameters. Mechanistically, the same block resolves SMILES constraints across passes in a fixed hierarchy: brackets first, rings second, and valence last, as shown by error classification and linear probing, with ablation isolating the bracket-matching head. Together, these results yield a compact, mechanistically interpretable molecular generator and a testbed for studying iterative computation in formal-language domains.
Apr 22, 2026

Mol-Debate: Multi-Agent Debate Improves Structural Reasoning in Molecular Design

Text-guided molecular design is a key capability for AI-driven drug discovery, yet it remains challenging to map sequential natural-language instructions with non-linear molecular structures under strict chemical constraints. Most existing approaches, including RAG, CoT prompting, and fine-tuning or RL, emphasize a small set of ad-hoc reasoning perspectives implemented in a largely one-shot generation pipeline. In contrast, real-world drug discovery relies on dynamic, multi-perspective critique and iterative refinement to reconcile semantic intent with structural feasibility. Motivated by this, we propose Mol-Debate, a generation paradigm that enables such dynamic reasoning through an iterative generate-debate-refine loop. We further characterize key challenges in this paradigm and address them through perspective-oriented orchestration, including developer-debater conflict, global-local structural reasoning, and static-dynamic integration. Experiments demonstrate that Mol-Debate achieves state-of-the-art performance against strong general and chemical baselines, reaching 59.82% exact match on ChEBI-20 and 50.52% weighted success rate on S2^2-Bench. Our code is available at https://github.com/wyuzh/Mol-Debate.